Your browser doesn't support javascript.
loading
Alzheimer disease.
Knopman, David S; Amieva, Helene; Petersen, Ronald C; Chételat, Gäel; Holtzman, David M; Hyman, Bradley T; Nixon, Ralph A; Jones, David T.
Afiliação
  • Knopman DS; Department of Neurology, Mayo Clinic, Rochester, MN, USA. knopman@mayo.edu.
  • Amieva H; Inserm U1219 Bordeaux Population Health Center, University of Bordeaux, Bordeaux, France.
  • Petersen RC; Department of Neurology, Mayo Clinic, Rochester, MN, USA.
  • Chételat G; Normandie Univ, UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging of Neurological Disorders", Institut Blood and Brain @ Caen-Normandie, Cyceron, Caen, France.
  • Holtzman DM; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.
  • Hyman BT; Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.
  • Nixon RA; Departments of Psychiatry and Cell Biology, New York University Langone Medical Center, New York University, New York, NY, USA.
  • Jones DT; NYU Neuroscience Institute, New York University Langone Medical Center, New York University, New York, NY, USA.
Nat Rev Dis Primers ; 7(1): 33, 2021 05 13.
Article em En | MEDLINE | ID: mdl-33986301
ABSTRACT
Alzheimer disease (AD) is biologically defined by the presence of ß-amyloid-containing plaques and tau-containing neurofibrillary tangles. AD is a genetic and sporadic neurodegenerative disease that causes an amnestic cognitive impairment in its prototypical presentation and non-amnestic cognitive impairment in its less common variants. AD is a common cause of cognitive impairment acquired in midlife and late-life but its clinical impact is modified by other neurodegenerative and cerebrovascular conditions. This Primer conceives of AD biology as the brain disorder that results from a complex interplay of loss of synaptic homeostasis and dysfunction in the highly interrelated endosomal/lysosomal clearance pathways in which the precursors, aggregated species and post-translationally modified products of Aß and tau play important roles. Therapeutic endeavours are still struggling to find targets within this framework that substantially change the clinical course in persons with AD.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Neurodegenerativas / Doença de Alzheimer / Disfunção Cognitiva Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Neurodegenerativas / Doença de Alzheimer / Disfunção Cognitiva Idioma: En Ano de publicação: 2021 Tipo de documento: Article